Voluntary withdrawal of 28 ANDAs
Sun Pharmaceutical Industries Ltd has informed BSE that one of the Company's wholly-owned subsidiaries has voluntarilyrequested the USFDA to withdraw approval for 28 Abbreviated New Drug Applications (ANDAs). These older drug products belong to erstwhile Ranbaxy Laboratories Ltd. and are not being marketed in the US since 2008. Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha S Valia Update on acquisition of Ocular Technologies, Sarl - closure of transaction
With reference to the earlier letter and Press Release dated October 26, 2016 regarding agreement to acquire100% equity stake of Ocular Technologies, Sarl.Sun Pharmaceutical Industries Ltd has now informed BSE that all the necessary formalities for closure of the said transaction have been concluded and the Company have successfully completed the acquisition of Ocular Technologies, Sarl, on December 15, 2016. Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jayant S Sanghvi Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pratham Investments Markets remain subdued; Sun Pharma drops 3%
Shares of information technology (IT) companies were trading higher by up to 8% on back of heavy volumes
Opening bell: Global equities rise ahead of US Fed decision; Sun Pharma in news
In other news, India's retail inflation eases to 3.63%in November as a squeeze in cash availability impacted prices of perishable commodities
USFDA finds lapses in testing methods, quality control at Sun Pharma's Halol unit
USFDA also found lapses in standard operating procedures during the inspection of Sun Pharma's Halol unit in Gujarat Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rakesh S Valia Sun Pharma & Moebius Medical sign exclusive global licensing deal to develop novel liposomal non-opiod pain product for osteoarthritis
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release titled "Sun Pharma & Moebius Medical sign exclusive global licensing deal to develop novel liposomal non-opiod pain product for osteoarthritis".